Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gossamer Bio, Inc.GOSS · Entity 6928 | COO/CFO | August 24, 2026 | August 26, 2026 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | May 07, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gossamer Bio, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Family Trust | 25 |
Reported balance
After 2026-08-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-24 · Grant · Acquired 25 · Balance 25 F1: Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued ("Stockholder Approval") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations. F2: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of Series A-1 non-voting convertible preferred stock. Following the Issuer's receipt of Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2036-08-23 | Direct | 5,800,051 |
Reported balance
After 2026-08-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-24 · Grant · Acquired 5,800,051 · Balance 5,800,051 F3: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued ("Stockholder Approval") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations.
F2: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of Series A-1 non-voting convertible preferred stock. Following the Issuer's receipt of Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of the Issuer's common stock.
F3: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Protagonist Therapeutics, Inc
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,825 |
Reported balance
After 2026-05-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-07 · Exercise / conversion · Acquired 24,000 · Balance 31,825 F1: Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust. |
| Common StockSEC Table I · non-derivative | Direct | 43,825 |
Reported balance
After 2026-05-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-05-07 · Exercise / conversion · Acquired 12,000 · Balance 43,825 |
| Common StockSEC Table I · non-derivative | Direct | 27,825 |
Reported balance
After 2026-05-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-05-07 · Sale · Disposed 36,000 · Balance 27,825 F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.69 to $104.67. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 12,695 |
Reported balance
After 2026-05-08 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-05-08 · Sale · Disposed 5,130 · Balance 12,695 |
| Common StockSEC Table I · non-derivative | IndirectBy Bryan & Courtney Giraudo Trust | 6,000 |
Reported balance
After 2026-05-07 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-05-07 · Sale · Disposed 12,000 · Balance 6,000 F1: Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Bryan & Courtney Giraudo Trust | 0 |
Reported balance
After 2026-05-08 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-05-08 · Sale · Disposed 6,000 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45 · Expires 2028-05-14 | Direct | 0 |
Reported balance
After 2026-05-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-07 · Exercise / conversion · Disposed 24,000 · Balance 0 F3: These stock options are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.98 · Expires 2028-05-28 | Direct | 0 |
Reported balance
After 2026-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-07 · Exercise / conversion · Disposed 12,000 · Balance 0 F3: These stock options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.69 to $104.67. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: These stock options are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2026 Filed Aug 26, 2026 22:10 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 5,800,051 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001740847-26-000006 · wk-form4_1787782215.xml · derivative · entry 2 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,800,051 Underlying: Common Stock · 5,800,051 shares Expires 2036-08-23 F3 · derivative.exercise_date: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 22:10 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantPre-Funded Warrant (Right to Buy) · Derivative | 25 | $1,000.00 Strike: $0.00 | $24,999.98 |
DisclosureSEC source: 0001740847-26-000006 · wk-form4_1787782215.xml · derivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 25 Underlying: Series A-1 Preferred Stock · 25 shares Expires not disclosed F1 · shares: Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued ("Stockholder Approval") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations. F2 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of Series A-1 non-voting convertible preferred stock. Following the Issuer's receipt of Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of the Issuer's common stock. F1 · derivative.underlying: Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued ("Stockholder Approval") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations. F1 · derivative.underlying_shares: Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued ("Stockholder Approval") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations. Read SEC document |
| May 08, 2026 Filed May 12, 2026 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 5,130 | $100.00 | $513,000.00 |
DisclosureSEC source: 0001104659-26-058860 · tm2614277-1_4seq1.xml · nonDerivative · entry 6 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,695 Read SEC document |
| May 08, 2026 Filed May 12, 2026 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 6,000 | $100.00 | $600,000.00 |
DisclosureSEC source: 0001104659-26-058860 · tm2614277-1_4seq1.xml · nonDerivative · entry 5 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bryan & Courtney Giraudo Trust Disclosed balance after: 0 Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001104659-26-058860 · tm2614277-1_4seq1.xml · derivative · entry 8 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001104659-26-058860 · tm2614277-1_4seq1.xml · derivative · entry 7 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2028-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 12,000 | $100.07 | $1,200,840.00 |
DisclosureSEC source: 0001104659-26-058860 · tm2614277-1_4seq1.xml · nonDerivative · entry 4 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bryan & Courtney Giraudo Trust Disclosed balance after: 6,000 F1 · balance_after: Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 36,000 | $100.14 | $3,605,040.00 |
DisclosureSEC source: 0001104659-26-058860 · tm2614277-1_4seq1.xml · nonDerivative · entry 3 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,825 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.69 to $104.67. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 12,000 | $6.98 | $83,760.00 |
DisclosureSEC source: 0001104659-26-058860 · tm2614277-1_4seq1.xml · nonDerivative · entry 2 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 24,000 | $6.45 | $154,800.00 |
DisclosureSEC source: 0001104659-26-058860 · tm2614277-1_4seq1.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 96,667 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 22 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,667 Underlying: Common Stock · 96,667 shares Expires 2029-03-25 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · shares: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 47,667 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 21 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,667 Underlying: Common Stock · 47,667 shares Expires 2030-02-14 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 20 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-25 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 19 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-09-15 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 176,667 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 18 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,667 Underlying: Common Stock · 176,667 shares Expires 2032-01-05 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 211,500 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 17 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,500 Underlying: Common Stock · 211,500 shares Expires 2032-12-06 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 211,500 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 16 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,500 Underlying: Common Stock · 211,500 shares Expires 2033-03-19 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 181,250 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 15 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,250 Underlying: Common Stock · 181,250 shares Expires 2033-11-19 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 543,750 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 14 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,750 Underlying: Common Stock · 543,750 shares Expires 2034-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 638,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 13 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638,000 Underlying: Common Stock · 638,000 shares Expires 2025-03-03 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 693,750 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 12 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 693,750 Underlying: Common Stock · 693,750 shares Expires 2036-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 96,667 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 11 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,667 shares Expires 2029-03-25 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 47,667 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 10 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,667 shares Expires 2030-02-14 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 9 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2031-02-25 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 8 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-09-16 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 176,667 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 7 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 176,667 shares Expires 2032-01-05 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 211,500 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 6 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 211,500 shares Expires 2032-12-06 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 211,500 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 5 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 211,500 shares Expires 2033-03-19 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 181,250 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 4 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 181,250 shares Expires 2033-11-19 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 543,750 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 3 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 543,750 shares Expires 2034-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 638,000 | Not disclosed Strike: $1.13 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 2 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 638,000 shares Expires 2035-03-03 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 693,750 | Not disclosed Strike: $2.88 | Not disclosed |
DisclosureSEC source: 0001740847-26-000004 · wk-form4_1774037809.xml · derivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 693,750 shares Expires 2036-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:39 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 693,750 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001740847-26-000002 · wk-form4_1767649172.xml · derivative · entry 3 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 693,750 Underlying: Common Stock · 693,750 shares Expires 2036-01-01 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on January 2, 2027 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:39 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 115,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001740847-26-000002 · wk-form4_1767649172.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,737 F1 · shares: Represents restricted stock unit award, which will vest in four equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:41 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 3,762 | $0.00 Strike: $87.18 | $0.00 |
DisclosureSEC source: 0001104659-26-001477 · tm262304-6_4seq1.xml · derivative · entry 3 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,762 Underlying: Common Stock · 3,762 shares Expires 2036-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:41 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 2,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001477 · tm262304-6_4seq1.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,825 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:13 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 181,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001740847-25-000003 · wk-form4_1759436009.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,987 F1 · shares: Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:04 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 638,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001728117-25-000010 · wk-form4_1741295043.xml · derivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638,000 Underlying: Common Stock · 638,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 4, 2026 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:07 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001428 · tm252003-3_4seq1.xml · derivative · entry 3 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:07 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001428 · tm252003-3_4seq1.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,130 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:21 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 100,000 | $0.59 | $59,110.00 |
DisclosureSEC source: 0001728117-24-000073 · wk-form4_1718929291.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 480,010 F1 · kind: The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 6,430 shares, with the Reporting Person's sale of 6,430 shares of common stock at a price of $1.1556 per share on March 27, 2024. The reporting person has agreed to pay to the Issuer $3,653.10, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 22:05 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 6,430 | $1.16 | $7,430.51 |
DisclosureSEC source: 0001728117-24-000039 · wk-form4_1711663523.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,737 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.1551 to $1.165 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 25,700 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-24-001491 · tm241954-3_4seq1.xml · derivative · entry 1 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,700 Underlying: Common Stock · 25,700 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:02 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 543,750 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001728117-24-000004 · wk-form4_1704405725.xml · derivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,750 Underlying: Common Stock · 543,750 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on January 2, 2025 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:07 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 181,250 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001728117-23-000147 · wk-form4_1700698050.xml · derivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,250 Underlying: Common Stock · 181,250 shares Expires 2033-11-19 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on November 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 23:24 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 200,000 | $0.56 | $112,880.00 |
DisclosureSEC source: 0001728117-23-000136 · wk-form4_1700004245.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 380,010 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.5557 to $0.5723 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:03 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock · Derivative | 13,505 | $0.13 Strike: $2.04 | $1,688.13 |
DisclosureSEC source: 0001728117-23-000100 · wf-form4_169040180880782.xml · derivative · entry 3 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 13,505 Underlying: Common Stock Purchase Warrants · 13,505 shares Expires 2028-07-24 Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:03 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 54,020 | $1.82 | $98,316.40 |
DisclosureSEC source: 0001728117-23-000100 · wf-form4_169040180880782.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 180,010 Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:15 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 176,667 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001728117-23-000053 · wf-form4_168366328309495.xml · derivative · entry 10 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,667 Underlying: Common Stock · 176,667 shares Expires 2032-01-05 F11 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F10 · price: On May 5, 2023, the Issuer canceled an option granted on January 6, 2022. In exchange for the canceled option, the reporting person received 176,677 options to purchase common stock having a lower exercise price with the same vesting terms. F9 · derivative.exercise_date: One-third of the total number of shares subject to the option vested on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:15 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001728117-23-000053 · wf-form4_168366328309495.xml · derivative · entry 9 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-09-16 F11 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F8 · price: On May 5, 2023, the Issuer canceled an option granted on September 16, 2021. In exchange for the canceled option, the reporting person received 100,000 options to purchase common stock having a lower exercise price with the same vesting terms. F7 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on September 16, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.